183: The Role of Cathepsin K in Extra Cellular Matrix Remodeling in Patients with End Stage Heart Failure

2010 ◽  
Vol 29 (2) ◽  
pp. S65-S65
Author(s):  
P. van der Weide ◽  
A.H. Bruggink ◽  
D.F. van Wichen ◽  
J. van Kuik ◽  
N. de Jonge ◽  
...  
2010 ◽  
Vol 16 (12) ◽  
pp. 931-937 ◽  
Author(s):  
Sanjoy Bhattacharya ◽  
Kaleab Abebe ◽  
Marc Simon ◽  
Samir Saba ◽  
Evan Adelstein

2015 ◽  
Vol 9s2 ◽  
pp. CMC.S19694 ◽  
Author(s):  
Allison McLarty

Heart failure is epidemic in the United States with a prevalence of over 5 million. The diagnosis carries a mortality risk of 50% at 5 years rivaling many diagnoses of cancer. Heart transplantation, long the “gold standard” treatment for end stage heart failure unresponsive to maximal medical therapy falls way short of meeting the need with only about 2,000 transplants performed annually in the United States due to donor limitation. Left ventricular devices have emerged as a viable option for patients as both a “bridge to transplantation” and as a final “destination therapy”.


2019 ◽  
pp. 331-340
Author(s):  
Lech Paluszkiewicz ◽  
Tomasz Kukulski ◽  
Michał Zembala ◽  
Jan Gummert ◽  
Michiel Morshuis

Sign in / Sign up

Export Citation Format

Share Document